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ABSTRACT  
The release and permeation studies were carried out for developing transdermal therapeutic systems 
with chlorpheniramine maleate (CPM). The patches were prepared with eudragit RS-100 and RL-100 
with/without polyvinyl pyrrolidone (PVP) and dibutyl phthalate (DBP) in different compositions. 
Thickness, tensile strength, drug content, moisture content and water absorption studies of the patches 
were measured. In vitro release/permeation of CPM was studied in modified Keshary-Chien diffusion 
cell. Chemical enhancers like l-menthol, oleic acid and phospholipon80 were added to compare the 
release pattern of the drug. The percent release of the drug from matrix patch increased with increase 
of PVP & DBP but the tensile strength decreased with the increase of DBP & PVP. Experimental 
release/permeation data of different formulations of the matrix systems are reported. Also the drug-
polymer interaction was investigated by ATR-FTIR studies. The discussion was correlated the 
efficient matrix dispersion patch from suitable eudragit polymers for transdermal antihistamine 
applications in film device industry. 
 
KEYWORDS: Matrix patch; Chlorpheniramine malaeate, Chemical enhancers, Dibutyl 
phthalate, Eudragit polymer, Polyvinyl pyrrolidone. 
 1. INTRODUCTION 
Eudragit polymers are widely used as coating material in the pharmaceutical formulations.1 These 
polymers are well tolerated by the skin and have high capacity for loading drugs. Some recent studies 
have been carried out with mixed ratios of Eudragit polymers (RS 100: RL 100, RLPO: RSPO) and 
with/without copolymers polyvinyl pyrrolidone (PVP) and polyethylene glycol 4000(PEG 4000) on 
transdermal drug delivery system.2-7. The primary role of plasticizers is to improve the flexibility and 
processability of polymers by lowering the second order transition temperature.8 Plasticizers are 
actually low molecular weight resins or liquids, which form secondary bonds to polymer chains and 
spread them apart. Thus, plasticizers reduce polymer-polymer chain secondary bonding and provide 
more mobility for the macromolecules, resulting in a softer, more easily deformable mass.9 
Chlorpheniramine, classified as an antihistamine, is a propylamine derivative (alkylamines) and has a 
Fecha de Recepción (Date received): 17/02/10 
Fecha de Aceptación (Date accepted): 10/03/10  
Ars Pharm, 2010, Vol.50 nº 4; 177-194. 
RAJABALAYA R. Design and in vitro evaluation of chlorpheniramine maleate…  178 
molecular weight of 390.87Da (chlorpheniramine maleate, CPM) Antihistamines such as CPM are 
H1-receptor antagonists and are utilized in the treatment of allergy. They prevent, but do not reverse 
the responses mediated by histamine. CPM antagonizes most of the pharmacological effects of 
histamine, including urticaria and pruritus. Also, CPM, like other antihistamines, produces a drying 
effect on various mucosas by preventing the responses to acetylcholine that are mediated via 
muscarinic receptors10,11. The CPM is a typical cationic amphiphilic amine drug (CAD); characterized 
by the hydrophobic ring structure of the molecule and the hydrophilic side chain with a charged 
cationic amino group. This above physiochemical property of CPM is similar to other CADs; therefore 
it was chosen as a model drug for the present study12. Specific objectives are: (1). to prepare CPM 
matrix patches with eudragit polymer, with/without PVP as the copolymer, with different percentages 
of dibutyl phthalate as the plasticizer and with/without enhancers. (2). to measure thicknesses and 
tensile strength of the matrix patches. (3). to measure the drug content & moisture content and also 
calculate water absorption capacities of high tensile strength patches. (4). to study the percentage 
release with/without chemical enhancers and permeation properties of CPM from the matrix patches 
by using modified keshary chien diffusion cell. (5). to study the possible drug-polymer interaction by 
ATR-FTIR and (6) to develop transdermal therapeutic system on the basis of the above data. 
2. MATERIALS AND METHODS  
2.1. Materials 
Eudragit RS 100 and RL 100 were gifted by Degussa India Ltd., Mumbai, India. Polyvinyl 
pyrrolidone (K-30) was purchased from SRL Pvt. Ltd., Mumbai, India. Chlorpheniramine maleate IP 
was gifted by Kontest Chemicals, Kolkata, India. L- Menthol B.P and Phospholin80 were gifted by 
Hindustan Mint & Agro Products Ltd, India and Natterman Phospholipid GMBH, Germany 
respectively. Oleic acid was purchased from Loba Chemie Pvt Ltd, Mumbai, India. Dibutyl Phthalate 
was purchased from Qualigens Fine Chemicals, Mumbai, India. These were used as received without 
any further purification. All other chemicals used in the study were of analytic reagent grade. 
2.2. Preparation of the patches 
For preparation of the patches, 400 mg of different eudragit grades were dissolved in 4 ml methanol 
followed by the addition of 20-80 mg PVP with uniform but slow magnetic stirring. Then the 
plasticizer (DBP:5-25% of the total polymer weight) and 16 mg of the drug (CPM) were added to the 
solution and stirred for 15–20 min. Next the total mass was slowly poured into the centre of SS rings 
having a backing layer of aluminium foil. The total mass was dried at room temperature for 48 h. 
2.3. Determination of patch thickness 
Patch thickness was measured by a digital micrometer (Mitutoyo, Japan). An average of six readings 
was tabulated (Table 1) 
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TABLE 1: Patch thickness and Tensile strength 
Average patch Thickness 
(mm) 
Average patch 
Tensile Strength (MPa) Patch code 
PVP 
(mg) 
DBP 
(%) 
R - RS 100 L - RL 100 R - RS 100 L - RL 100 
R/L 1 - 10 0.11 ± 0.01 0.09 ± 0.01 6.83 ± 0.91 5.86 ± 1.02 
R/L 2 - 15 0.11 ± 0.01 0.10 ± 0.05 7.43 ± 0.09 5.71 ± 1.02 
R/L 3 - 20 0.11 ± 0.04 0.11 ± 0.03 6.34 ± 1.26 5.60 ± 1.02 
R/L 4 - 25 0.11± 0.01 0.11 ± 0.01 6.26 ±0.99 4.27 ± 0.01 
R/L 5 40 10 0.11± 0.01 0.11 ± 0.02 4.10 ± 0.62 4.48 ± 0.37 
R/L 6 40 15 0.12 ± 0.04 0.11 ± 0.02 5.38 ± 0.05 5.30 ± 0.41 
R/L 7 40 25 0.12 ± 0.01 0.11 ± 0.03 3.98 ± 0.88 5.12 ± 0.63 
R/L 8 60 10 0.13 ± 0.08 0.11 ± 0.02 3.00 ± 0.21 5.60 ± 0.65 
R/L 9 60 20 0.13 ± 0.08 0.12 ± 0.01 4.76 ± 0.10 3.53 ± 1.08 
R/L 10 80 15 0.14± 0.02 0.13 ± 0.01 3.52 ± 0.86 3.10 ± 0.99 
R/L 11 80 25 0.14 ± 0.05 0.14 ± 0.02 3.17 ±1.13 2.95 ± 1.52 
Notations:  
R - RS 100; L - RL 100 
All formulations contain 400 mg of polymer and 16mg of CPM. 
Example: R 1 means: RS 100 - 400mg + PVP-Nil + CPM-16mg + DBP-10% 
2.4. Determination of tensile strength  
The tensile strength of the patches was evaluated using Instron 4204, UK tensilometer with a mounted 
load of 50KN. Six samples of same formulation were tested with extension speed at 5mm/min 
[American society for testing materials(ASTM); method D 882- 75D]. The test was carried out at 
25±2°C and 56± 2% RH. The tensile strength was calculated as follows  
τ = L max/ Ai
Where τ is the tensile strength; L max is the maximum load and Ai is the initial cross sectional area of 
the sample. An average of six readings was tabulated. (Table 1) 
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2.5. Drug content 
A known area of each patch was weighed accurately, dissolved in 2ml of casting solvent and the 
volume was diluted with distilled water and filtered. For the drug content in each formulation, 6 
patches were analyzed spectrophotometrically at 267nm. A control was also performed using a drug 
free film. An average of six readings was tabulated. (Table 2) 
TABLE 2: Drug content and Moisture content 
Drug content (µgm/cm2) Moisture content (Wt %) 
Patch code 
R - RS 100 L - RL 100 R - RS 100 L - RL 100 
R/L 1 567 ± 0.01 564 ± 0.18 0.675 ± 0.57 1.112 ± 0.91 
R/L 2 571 ± 0.43 567 ± 0.45 0.663 ± 0.67 1.102 ± 1.02 
R/L 3 574 ± 0.53 570 ± 0.61 0.634 ± 0.53 1.002 ± 1.02 
R/L 4 579 ± 0.84 574 ± 0.11 0.621 ± 0.48 0.987 ± 0.01 
R/L 5 - 563 ± 0.29 - 1.123 ± 0.37 
R/L 6 567 ± 0.46 565 ± 0.38 0.743 ± 0.05 1.118 ± 0.41 
R/L 7 572 ± 0.76 570 ± 0.43 0.729 ± 0.62 1.004 ± 0.63 
R/L 8 - 565 ± 0.74 - 1.217 ± 0.65 
R/L 9 573 ± 0.96 - 0.756 ± 0.10 - 
 
2.6. Moisture content 
The patches were weighed individually and kept in a desiccator containing fused calcium chloride at 
40º C for 24 hours9. The patches were reweighed until a constant weight was obtained. Moisture 
content was calculated in percentage based on the difference between the initial and the constant final 
weights of the patches. An average of three readings was tabulated (Table 2). 
2.7. Water absorption studies 
For the determination of water absorption capacity, weighed patches were kept at room temperature 
for 24 hours exposed to two relative humidities of 75% (containing saturated solution of sodium 
chloride) and 93% (containing saturated solution of ammonium hydrogen phosphate) in different 
desiccators at room temperature. The water absorption capacity of the patches was determined in 
terms of percentage increase in the weight of the patch over its initial weight. Periodically the weights 
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were taken until constant weight was obtained. An average of three readings was tabulated (Table 3). 
TABLE 3: Water absorption studies 
Water absorption studies  
75% RH (Wt %) 
Water absorption studies 93% 
RH (Wt %) Patch code 
R - RS 100 L - RL 100 R - RS 100 L - RL 100 
R/L 1 1.143 ± 0.91 2.231 ± 0.91 2.814 ± 0.57 4.421 ± 0.91 
R/L 2 1.132 ± 1.02 2.201 ± 1.02 2.769 ± 0.67 4.403 ± 1.02 
R/L 3 1.126 ± 1.02 2.193 ± 1.02 2.682 ± 0.53 4.391 ± 1.02 
R/L 4 1.109 ± 0.01 2.178 ± 0.01 2.625 ± 0.48 4.384 ± 0.01 
R/L 5 - 2.471 ± 0.37 - 4.478 ± 0.37 
R/L 6 1.154 ± 0.41 2.412 ± 0.41 2.873 ± 0.05 4.421 ± 0.41 
R/L 7 1.142 ± 0.63 2.346 ± 0.63 2.861 ± 0.62 4.402 ± 0.63 
R/L 8 - 2.512 ± 0.65 - 4.493 ± 0.65 
R/L 9 1.173 ± 1.08 - 2.903 ± 0.10 - 
 
2.8. Attenuated total reflectance-Fourier transform infrared (ATR-FTIR) 
The patches analyzed were by attenuated total reflectance-Fourier transform infrared (ATR-FTIR) on 
a Magma-IR™ Spectrometer 750 (Nicolet Instrument Corp.), equipped with a Golden Gate Single 
Reflection Diamond ATR. Spectra were recorded on an average of 32 scans with a resolution of 
4 cm−1 and in the frequency range of 400 to 4000 cm−1 (Table 4). 
TABLE 4: Functional group assignment ATR- FTIR studies 
Wave number (cm-1) 
Materials 
Standard Test 
Peaks for functional groups assignment 
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Eudragit  
RS100/ RL100 
 
 
2962-2853 
~1340 
1485-1445 
1750-1735 
1680-1620 
~1410 
1220-1020 
800-600 
2952,2956,2852 
1386 
1456,1481,1479 
1733 
1635 
1386 
1149, 1147 
667,653,651,752 
C–H Stretching, alkane 
C–H Stretching, alkane (RS&RL100) 
C–CH2 bending, alkane  
RCOO - Strong band of ester group 
C–C Multiple bond stretching  
N–R quaternary amine salts 
C–N Vibration, aliphatic  
C–Cl Vibration, aliphatic 
PVP 
2962-2853 
1680-1630 
1485-1445 
~1340 
1360-1310 
~830 
2954 
1672 
1463 
1375 
1290 
844 
C–H Stretching, alkane 
N-C=O carbonyl stretching vibrations on 
amides  
C– CH2 Bending, alkane 
C–H Bending, vinyl 
C–N Vibration, aromatic tertiary 
C–H Bending aromatic 2 adjacent 
hydrogen atom 
CPM 
~3030 
2962-2853 
~1450 
1400-1300 
1350-1280 
1220-1020 
995-985 
800-600 
~780 
3012 
2942 
1473 HI 
1357 
1205 
1151 
971 
717,649 
763 
C–H Stretching aromatic vibration 
C–H Stretching, alkane 
C–C Multiple bond stretching, aromatic  
COOH carboxylate anion Stretching 
C–N Vibration, aromatic 2° amine 
C–N Vibration, aliphatic tertiary amine 
CH=CH Bending, alkene 
C–Cl Vibration, aliphatic 
C–H Bending aromatic adjacent 3 
hydrogen atom 
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RS/RL:PVP:CP
M 
patches 
Scanned 1cm2 
patch 
containing 
585µgm 
2962-2853 
1750-1735 
1680-1620 
1680-1630 
1485-1445 
~1410 
1400-1300 
1360-1310 
1350-1280 
1220-1020 
1220-1020 
800-600 
~830 
~780 
2954 
1724 
1656 
1643 
1461 
1438 
1384 
1357 
1274 
1145 
1074 
748 
842 
705 
C–H Stretching, alkane 
RCOO - Strong band of ester group 
C–C Multiple bond stretching  
N-C=O carbonyl stretching vibrations on 
amides  
C–CH2 bending, alkane  
N–R quaternary amine salts 
COOH carboxylate anion Stretching 
C–N Vibration, aromatic tertiary 
C–N Vibration, aromatic 2° amine 
C–N Vibration, aliphatic tertiary amine 
C–N Vibration, aliphatic  
C–Cl Vibration, aliphatic 
C–H Bending aromatic 2 adjacent 
hydrogen atom 
C–H Bending aromatic adjacent 3 
hydrogen atom 
 
2.9. In vitro release study 
The invitro release studies were carried out in a modified Keshary – chien diffusion cell. A piece of 
matrix patch (circular) was mounted carefully on the donor compartment. The donor compartment was 
empty and the backing membrane side of the matrix patch was open to the atmosphere but the receptor 
compartment was filled with freshly prepared phosphate buffer saline solution of pH 7.4. The receptor 
compartment was maintained at 32 ± 0.5°C by circulating water in the surrounding jacket and by slow 
stirring of the receptor liquid by a magnetic stirrer at 40-50 rpm. The volume of the receptor liquid 
was such that the matrix patch piece (drug side) just touched the receptor liquid surface horizontally 
for molecular diffusion. The samples were withdrawn at different intervals and replaced immediately 
with the same volume of saline solution. Samples were analyzed spectrophotometrically at 276nm 
after suitable dilution. An average of three readings was tabulated (Table 5). 
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TABLE 5: Cumulative percentage release and rate after 8 hour 
Average cumulative  
release (%) 
Average release rate 
µgm/cm2.hr Patch 
code R - RS 100 L - RL 100 R - RS 100 L - RL 100 
R/L 1 31 32 4 21 
R/L 2 38 75 20 25 
R/L 3 42 82 22 27 
R/L 4 68 89 25 30 
R/L 5 36 82 - 13 
R/L 6 40 94 6 12 
R/L 7 59 - 27 - 
R/L 8 - - - - 
R/L 9 68 - 17 - 
2.10. In vitro skin permeation study 
 TABLE 7 :Cumulative percentage permeation and rate after 8 hour 
Patch code 
Average cumulative 
permeation (%) 
Average permeation  rate, 
µgm/cm2.hr  
R 2 16 8 
R 3 19 12 
R 4 42 29 
R 5 Pb 30 16 
R 6 Pb 39 17 
L1 Mb 56 32 
L1 Ob 55 39 
ML2 50 20 
ML3 56 24 
ML4 57 27 
A section of the freshly excised albino mouse abdominal skin treated in isotonic solution was bound 
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intimately with a matrix patch piece without any air gap, on the donor compartment. The dermal side 
of the skin just touched the receptor liquid surface horizontally for permeation of the drug. The 
temperature of the receptor liquid, the rate and method of stirring, the sample collection and the 
sample analysis methods were similar to those during release study (Table 7). 
3. RESULTS AND DISCUSSION 
3.1. Physiochemical and mechanical properties 
RS 100 and RL 100 with/without PVP and with DBP were used to prepare the matrix patches, Table 1 
allows some interesting conclusions to be drawn. Patches from RL 100 have a lower tensile strength 
compared to those with RS 100. This may be due to high miscibility of hydrophobic RS 100 polymer 
with the drug CPM and DBP. Moreover, increasing PVP, in patches, decreases the tensile strength in 
all cases. Addition of more PVP, (R/L 5 – R/L 11)) reduces the matrix tensile strength as well as its 
elasticity13,14. This could be due to either PVP destroyed the continuity of polymer chain molecules, 
resulting in a decrease in the blended polymer strength or decreases internal stresses of main polymer 
of eudragit15.  
The moisture content of the RL 100 patches was higher compared to relatively hydrophobic nature of 
Eudragit RS 100 patches and also hydrophilic nature of RL 100 is responsible for increasing the 
amount of water absorbed by the patches, as shown in experiments involving two different moist 
atmospheres namely in 75% and 93% RH. Tables 2 & 3 show that the DBP has limited water 
solubility so it was difficult to hydrate the patch in higher percentage during the moisture content and 
water absorption studies. The hydrophilic nature of PVP has also to be taken into account with regard 
to the higher moisture content of the patches due to their higher PVP content. Similarly the water 
absorption under both RH conditions is also higher at higher PVP contents in the matrix patches. 
Eudragit RL 100 with PVP patches (L 5 - L 8) showed surface cracks and pores during the water 
absorption studies. Eudragit RL100 film plasticized with any of the plasticizers took up water a 
hundred times its weight and this may be attributed to the higher hydrophilic property of Eudragit RL 
film which rapidly broke during the water absorption studies16. Hence these were deleted from in vitro 
release studies because this type of matrix patches will not be stable during wound care therapy hence 
the patch needs needed balance in hydrophilic and hydrophobic nature17-19.  
Table 2, the matrix patches having more than 20% of DBP with PVP is more flexible and adhesive in 
nature due to two important reasons, which is CPM itself acting as a plasticizer. [10] The second reason 
is that the addition of PVP resulted the significant increase of the matrix cohesion was due to 
interactions between the amide group of PVP and the carboxylic acid group of PMMA. Solid solutions 
of chlorpheniramine in Eudragit1 RL or RS films exhibited a decrease of Tg values when the 
concentrations of the drugs in the polymeric films were increased20-21. So the present study report will 
be promising for possiblilty in potential transdermal, wound care and with hot melt extrusion 
Ars Pharm, Vol. 50 nº4; 177-194 
RAJABALAYA R. Design and in vitro evaluation of chlorpheniramine maleate…  186 
technology film fabrication as earlier reported extrusion of CPM with HPC based polymer11. From the 
literatures and mechanical engineering handbooks, it is well known that the materials having a value 
more than 4.0 MPa are elastic in nature. Therefore in vitro release studies were carried out for only 
those patches having suitable physiochemical properties and more than 4.0MPa tensile strength.  
3.2. ATR-FTIR studies 
A comparison of the ATR-FTIR spectrums of the individual polymers/drug like eudragit RS 100, RL 
100, PVP and CPM and also formulation matrix patch was carried out to observe any spectral shifts in 
the matrix. The FTIR spectra of the drug CPM, polymers (eudargit RS 100 & RL 100, PVP and 
formulation matrix patches are depicted in Fig. 1. The group assignments are discussed in Table 4. 
The FTIR spectra of the optimized formulations RS 100: PVP: CPM as well as RL 100: PVP: CPM 
[Scanned 1cm2 patch containing 585µgm] revealed all the peaks of the polymers. The characteristics 
of eudragit RS 100 and PVP peaks were observed at 2954cm-1 and 1724cm-1, 1643cm-1, 1656cm-1, 
1643cm-1, 1438 cm-1, and 842cm-1 respectively. No significant shifts in the peaks corresponding to the 
drug or polymers were observed in the formulation matrix. Some characteristic peaks corresponding to 
the drug were found to be overlapping in the region as that of the polymer. 
FIG. 1: ATR FTIR Graphs: A: Eudragit RS 100; B: Eudragit RL 100; C: PVP; D: CPM; E: RS 
100 Matrix patch; Figure: RL 100 Matrix patch 
 
Wave number cm-1
3.3. In vitro release studies 
The percentage cumulative release and release rate (µgm/cm2.hr) after 8 h of diffusion from both RS 
100 and RL 100 matrix patches are shown in Table 5. From this data, it can be seen that as the amount 
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of DBP in matrix patch increases, the percentage release also increases; however in the case of RL 
100, the release is maximum (even without PVP: L1 - L4: 32 – 89 %) than RS 100 patches (R1 – R4: 
31 – 68 %). As stated earlier above 20% of DBP with PVP like R7 and R9 is sticky in nature though it 
released 59 & 68%, but in irregular passion. The cumulative release of drug on a percentage basis 
from the matrix patch was plotted with time (t1/2) in Fig. 2 and Fig. 3. From the plots, it is clear that the 
release of the drug from the patches followed the diffusion controlled matrix model in which the total 
percentage of drug released is proportional to the square root of time. The cumulative release from the 
RS 100 matrix patches (Fig. 1) follows Fick’s law of diffusion. The plots of R2, R3 and R4, when 
extrapolated to the origin, may be considered as linear and follow Higuchi release while rest of the 
plots of RS 100 are not linear and do not follow Higuchi release. Higuchi developed an equation 
(percentage release = Kt1/2) for the release of a drug from a homogeneous polymer matrix-type 
delivery system that indicates the amount of drug released is proportional to the square root of time22. 
In both cases, R/L 4 (25% DBP) exhibit the maximum percentage release compared to others. Release 
of a drug from a transdermal drug delivery system mainly involves diffusion factors23. This is 
probably due to two reasons the first one is that the greater uniform distribution of drug in the polymer 
matrix, the greater surface diffusion, while the other reason is the presence of a greater amount of DBP 
relaxing the polymer chain which increase the rate of diffusion. The patch released cumulative amount 
of CPM in the order R/L 1 > R/L 2 > R/L 3 > R/L 4. 
FIG. 2: Release profile of RS 100 patches 
 
A break in each plot in Fig. 3 is observed in RL 100 matrix patches, each plots after the break also 
follow Fickian diffusion but do not follow Higuchi release. The total drug release increases with the 
increasing time of release but the total release as a percentage after 8 h is greater in RL 100 compared 
to the corresponding RS 100 (L1 –L4 >R1- R4) due to higher hydrophilic property of Eudragit RL 100 
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allow the permeant freely (responsible of its ammonium group), thereby promoting the dissolution, 
and hence higher release of water-soluble drug24,25. Moreover, with PVP patches like (L5 & L6) are 
polymer would leach out and, hence, create more pores and channels for the higher drug release26. 
Also the active path thickness of diffusion decrease leads to bursting effect as well as the release 
percentages increases.  
FIG. 3: Release profile of RL 100 patches 
 
3.4. Effect of chemical enhancers on the release of CPM  
To observe the enhancer effect R1, R5 and R6 patches were chosen as its tensile strength is 
appreciably high and cumulative release is lowest (31 – 40 %). Oleic acid and phospholipon 80 of 
different percentages were added (Table 6). The percent release increases with oleic acid but not 
appreciably, may be due filling of oleic acid between the polymer chain spacing and blocks the 
diffusion path channel with primary plasticizer of DBP. Many literatures have stated that oleic acid 
acts as a secondary plasticizer leads to lesser release of drug27. Phospholipon 80 either patch quality or 
the release percentages increased may be due to greater miscibility in the polymer drug matrix and 
thus increasing the average polymer chain spacing. 
Many studies have employed phospholipids as vesicles (liposomes) to carry drugs into and through 
human skin. However, none of the studies have used phospholipids in a non-vesicular form as 
penetration enhancers28. This is the first time this enhancer is incorporated in to the matrix system. All 
the release profiles follow fickian diffusion, therefore the patches are containing 2% phospholipids 80 
(R5 Pb and R6 Pb) considered for permeation (Fig.4).  
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FIG. 4: Release profile of RS 100 patches with chemical enhancers 
 
The matrix patch L1 having reasonably high tensile strength and fairly uniform release rate was 
considered for observing the effect of chemical enhancers on its release profiles. The enhancers used 
were L-menthol, oleic acid and phospholipon 80 (1%, 2% and 3% of the total patch weight). The 
compositions and experimental release data for different patches are tabulated in Table 6 except 
phospholipon 80 because it was observed during and after the release studies that the patches were 
either swollen or the patches contained some surface cracks. The Fig. 5 and table 6 shows that the 
cumulative percent releases as well as release rate appreciably increased with 2% L-menthol & oleic 
acid (75 &76%) and show maximum release, incase of 3% L-menthol shows higher release but with 
few surface cracks, hence only 2% enhancers patches (L1 Mb & L1 Ob) were chosen for the 
permeation studies. 
FIG. 5: Release profile of RL 100 patches with chemical enhancers 
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TABLE 6 Cumulative percentage release and rate with enhancers data 
Patch 
code P/O/M (%) 
% Release 
after 8 hours 
Release rate 
after 8thhour,µgm/cm2.hr 
 a b c a b c a b c 
R 1 P P/O P/O 44 53/45 54/49 12 13/26 20/21 
R 5 P P P 36 59 61 13 19 28 
R 6 P P P 43 62 83 8 21 33 
L1 M/O M/O M/O 65/73 75/76 89/84 10/6 11/20 18/27 
Notations:P: Phospholipon 80;O: Oleic acid; M:L-menthol (a-1%, b-2%  and c -3%).  
Eg. R5 Pb: 2% phospholipon 80 
3.5. In vitro skin permeation studies 
Considering all the factors like tensile strengths, better physiochemical properties, percent release, 
release rate, patch quality before and after release, surface smoothness and initial bursting effect of the 
patches, R2, R3, R4, R5Pb and R6Pb (RS100) and L1 Mb, L1 Ob, L2, L3 and L4 (RL 100) were 
selected for permeation studies. The cumulative permeation on a percentage basis after 8 h of 
permeation through RS 100 and RL 100 matrix patches and biological membrane (mouse skin) are 
also shown in Table 7. From this data, it can be seen that the R 4 and R 6 Pb matrix patches have the 
highest permeation, 42 % and 39 % respectively. Hence phospholipids is more suitable enhancer with 
RS 100 as reported earlier because it can occlude the skin surface and thus can fuse with stratum 
corneum lipids and increase tissue hydration, which, as shown above, can increase CPM permeation28.  
FIG. 6: Permeation profile of RS 100 patches 
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FIG. 7: Permeation profile of RL 100 patches 
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In the case of RL 100 patches the permeation of all the patches were regular, with higher percent 
permeation and uniform in nature. The cumulative release rate with L-menthol and oleic acid was 
higher mainly due to l-menthol which acts by disrupting the lipid structure of the stratum corneum, 
thereby increasing the diffusion coefficient of the drug in the skin membrane and a fluidizing action on 
the ceramide alkyl chains organization, increasing spacing of the lipid bilayer packing of the skin 
respectively29-31.The in vitro drug release and skin permeation studies showed that the skin is the rate-
limiting factor because the in vitro release of the drug was greater from each type of the matrix patch 
compared with the respective in vitro drug permeation rate. The cumulative drug permeation as a 
percentage from RS 100 and RL 100 patches was plotted against the permeation time in hours (t) in 
Fig. 6 and Fig. 7 respectively. In each plot, the rate of drug permeation is fairly constant over time and 
the permeation profiles exhibit the concentration dependent first-order kinetics. 
4. CONCLUSIONS  
The percentage release and permeation from the RL 100 formulations are greater than the 
corresponding values of the RS 100 formulations, the other physical properties like patch thickness 
and tensile strength are slightly lower compared to RS 100 patches. The average moisture content and 
water absorption capacities of any RL 100 formulation are greater, hence proper packaging and 
storage of such RL 100 patches would be necessary. Percentages water absorption of RL 100 with 
PVP patches at different relative humidities is also higher compared to RS 100 patches. These physical 
properties also rule out the RL 100 with PVP patches from any further studies. Therefore, from the 
above observations, it may be concluded that (i). Polymer Eudragit RS 100 is suitable for making of 
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CPM matrix patch. (ii). DBP (25%) is the plasticizer of choice, however with 2% phospholipon80 as 
the enhancers may need only 15% of DBP for RS 100. (iii). PVP (copolymer) may be added in 
minimum amount in RS 100 formulation patches however it may require 2% phospholipon 80 as the 
chemical enhancer. (iv). In the case of RL 100, the copolymer PVP is not required, however it may be 
added (depends upon the release pattern required by the patient) chemical enhancers like 2% L 
menthol and oleic acid.  
The patches R4, R6 Pb and all rest of the RL 100 patches are probably the best possible TD matrix 
patch composition for the uniform and continuous release/permeation of CPM for long period and for 
maintaining a sustained therapeutic level of the drug in plasma. These selected formulations may be 
used for further pharmacokinetic and pharmacodynamic studies in suitable animal models. 
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